Stonebridge Financial Group, LLC/CA’s Vertex Pharmaceuticals VRTX Stock Holding History

Stonebridge Financial Group, LLC/CA’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+465	New	+$206K	0.03%	267

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Stonebridge Financial Group, LLC/CA's VRTX Position: Q2 2026 in Review

Stonebridge Financial Group, LLC/CA opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 465 shares worth $230K. The stake represents 0.03% of the portfolio and ranks #267 among its holdings.

1,436 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Stonebridge Financial Group, LLC/CA held 465 shares of Vertex Pharmaceuticals worth $230K as of Q2 2026.
Vertex Pharmaceuticals was a new Stonebridge Financial Group, LLC/CA position in Q2 2026.
Vertex Pharmaceuticals made up 0.03% of Stonebridge Financial Group, LLC/CA's portfolio in Q2 2026, its #267 holding.
1,436 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Stonebridge Financial Group, LLC/CA's 13F filing for Q2 2026, filed 13 Aug 2026.